Lloyd Lanz

HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD’s The Liver Meeting 2024

HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD’s The Liver Meeting 2024

October 24, 2024

HONG KONG, Oct 25, 2024 - (ACN Newswire) - HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the...

Cytomos raises $5m to scale up cell analysis technology production

November 21, 2024

Researchers zero in on genetic variant tied to miscarriages

Researchers zero in on genetic variant tied to miscarriages

November 21, 2024

Cities, states say they’ll need more help to replace millions of lead pipes

Cities, states say they’ll need more help to replace millions of lead pipes

November 21, 2024

Nationwide, couple-based reproductive carrier screening program demonstrates feasibility

Nationwide, couple-based reproductive carrier screening program demonstrates feasibility

November 21, 2024

Study assesses risk for 28-day hospitalization for adults with RSV

Study assesses risk for 28-day hospitalization for adults with RSV

November 21, 2024